Consumers, patients and clinicians have long wrestled with the safety issues of phytoestrogens regarding the breast and uterine endometrium in particular. Phytoestrogens are used for both prevention and treatment strategies in areas of bone health, cardiovascular issues, bone density, hot flashes and more. Research has been debated regarding their effects on endometrial or breast tissues. […]
Read Full Post »
Menopausal hormone therapy is prescribed to address menopause related symptoms, as well as to reduce risks of several chronic diseases and to treat select conditions. Despite its significant benefits, there are slight risks, and there are occasionally nuisance issues that require attention. One of these is breast tenderness. Breast tenderness can be caused by estrogen […]
Read Full Post »
One of the most common experiences of menopause are the changes that occur on the external genital tissue and intravaginal tissue that can then also affect urinary function. This is called genitourinary atrophy, and most recently coined, genitourinary syndrome of menopause. Symptoms can include one or more of the following: vulvovaginal discomfort, itching, burning, tingling, […]
Read Full Post »
Vulvovaginal thinning, known as atrophic vaginitis, or more recently, genitourinary syndrome of menopause, is the thinning and drying of vulvovaginal mucosa associated with lower estrogen levels, often seen in perimenopause and menopause. Symptoms include vulvovaginal discomfort, dryness, burning, itching, and dyspareunia. Intravaginal and/or topical vulvar estrogen is the conventional treatment of choice. Sea buckthorn (Hippophae […]
Read Full Post »
Posted in Hormone Replacement, Menopause on Aug 30th, 2012
This study is the first randomized placebo-controlled trial of oral micronized progesterone (OMP) for hot flushes and night sweats, aka vasomotor symptoms (VMS). Postmenopausal women within 1 to 10 years of their last menstrual period and experiencing VMS that met the entrance required minimum for both frequency and intensity. The 133 women were randomized to […]
Read Full Post »
A new publication from the Women’s Health Initiative (WHI) focused on the effects of estrogen and progestin (conjugated equine estrogens 0.625 mg/day and 2.5mg/day medroxyprogesterone acetate = Prempro) on breast cancer incidence mortality after an average follow-up of 11 years, through August 2009. The new information from this now 11 year body of information translates […]
Read Full Post »
One of the more newsworthy items of late, has been the decline of breast cancer seen in 2003. The rate of breast cancer in women in the U.S. fell significantly by 6.7% in 2003, according to data from the National Cancer Institute (NCI) registries. Data from 2004, showed a leveling off, with no real additional […]
Read Full Post »
